Rational engineering of minimally immunogenic nucleases for gene therapy.
Raghavan R, Friedrich MJ, King I, Chau-Duy-Tam Vo S, Strebinger D, Lash B, Kilian M, Platten M, Macrae RK, Song Y, Nivon L, Zhang F
Nat Commun. 2025 Jan 2;16(1):105. doi: 10.1038/s41467-024-55522-1.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 235231 | Redi.2.SaCas9-L9S-I934K-L1035V | Expresses reduced immunogenicity variant of SaCas9 (Redi.2.SaCas9) with mutations L9S, I934K, L1035V. Has AAV ITRs |
| 235234 | Redi.1.AsCas12a-L218S-I285S-L972A | Expresses reduced immunogenicity variant of AsCas12a (Redi.1.AsCas12a) with mutations L218S, I285S, L972A. |
| 235236 | Redi.3.AsCas12a-L218T-I285A-L972A | Expresses reduced immunogenicity variant of AsCas12a (Redi.3.AsCas12a) with mutations L218T, I285A, L972A. |